Intellia Therapeutics Presents Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran at ACAAI 2026
Intellia Therapeutics announced new clinical and patient-reported data for its CRISPR-based therapy, lonvoguran ziclumeran (lonvo-z), demonstrating significant reductions in hereditary angioedema attack rates.